Collegium Pharmaceutical (COLL)
(Delayed Data from NSDQ)
$36.42 USD
+0.58 (1.62%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $36.45 +0.03 (0.08%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth D Momentum A VGM
Cash flow Statements
Fiscal Year End for Collegium Pharmaceutical, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | 48.16 | -25.00 | 71.52 | 26.75 | -22.72 |
Depreciation/Amortization & Depletion | 148.02 | 138.94 | 68.92 | 61.55 | 15.48 |
Net Change from Assets/Liabilities | 21.73 | -12.71 | 13.49 | -25.30 | 18.18 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 56.84 | 23.01 | -50.36 | 30.94 | 16.84 |
Net Cash From Operating Activities | 274.75 | 124.23 | 103.56 | 93.94 | 27.78 |
Property & Equipment | -0.46 | -1.62 | -1.94 | -5.55 | -6.44 |
Acquisition/ Disposition of Subsidiaries | 0.00 | -572.07 | 0.00 | 0.00 | 0.00 |
Investments | -70.35 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | -368.23 | 0.00 |
Net Cash from Investing Activities | -70.81 | -573.69 | -1.94 | -373.77 | -6.44 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | -65.90 | -1.92 | -35.15 | 7.34 | 2.86 |
Issuance (Repayment) of Debt | -65.92 | 442.68 | -50.00 | 281.39 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -8.36 | -4.04 | -4.15 | -2.26 | -0.82 |
Net Cash from Financing Activities | -140.18 | 436.72 | -89.30 | 286.47 | 2.04 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 63.76 | -12.74 | 12.31 | 6.64 | 23.39 |
Cash at Beginning of Period | 176.24 | 188.97 | 176.66 | 170.02 | 146.63 |
Cash at End of Period | 239.99 | 176.24 | 188.97 | 176.66 | 170.02 |
Diluted Net EPS | 1.29 | -0.74 | 1.86 | 0.76 | -0.68 |
Fiscal Year End for Collegium Pharmaceutical, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | 48.16 | 16.22 | -4.42 | -17.43 |
Depreciation/Amortization & Depletion | NA | 148.02 | 113.13 | 76.54 | 38.28 |
Net Change from Assets/Liabilities | NA | 21.73 | 23.83 | 15.01 | -24.86 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 56.84 | 48.24 | 40.26 | 31.68 |
Net Cash From Operating Activities | NA | 274.75 | 201.41 | 127.39 | 27.67 |
Property & Equipment | NA | -0.46 | -0.30 | -0.23 | -0.18 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | NA | -70.35 | -45.42 | -41.66 | 0.00 |
Other Investing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | NA | -70.81 | -45.72 | -41.89 | -0.18 |
Uses of Funds
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | -65.90 | -44.14 | 5.27 | 4.02 |
Issuance (Repayment) of Debt | NA | -65.92 | -20.08 | 25.75 | 72.02 |
Increase (Decrease) Short-Term Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | -8.36 | -8.13 | -7.96 | -7.74 |
Net Cash from Financing Activities | NA | -140.18 | -72.35 | 23.06 | 68.30 |
Effect of Exchange Rate Changes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | NA | 63.76 | 83.34 | 108.56 | 95.79 |
Cash at Beginning of Period | NA | 176.24 | 176.24 | 176.24 | 176.24 |
Cash at End of Period | NA | 239.99 | 259.58 | 284.80 | 272.03 |
Diluted Net EPS | NA | 0.93 | 0.53 | 0.34 | -0.51 |